Clinical Trial Update: Clazosentan in Aneurysmal Subarachnoid Hemorrhage [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating clazosentan for aneurysmal subarachnoid hemorrhage has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aneurysmal Subarachnoid Hemorrhage

Drugs mentioned

• Clazosentan (clazosentan)

Snippet

Sponsor: Idorsia Pharmaceuticals Ltd. | Conditions: Aneurysmal Subarachnoid Hemorrhage | Phase 3 | Status: TERMINATED